Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS).

(2017) K. Pietzner et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

(2010) Diane Seimetz et al.   CANCER TREATMENT REVIEWS

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Have we overestimated the benefit of human(ized) antibodies?

(2010) Daniel R. Getts et al.   mAbs

Functional and clinical consequences of Fc receptor polymorphic and copy number variants

(2009) S. Bournazos et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

(2009) Michael A Strohlein et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Monoclonal antibodies for cancer immunotherapy

(2009) Louis M Weiner et al.   LANCET

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody

(2008) Shoshana Morecki et al.   EXPERIMENTAL HEMATOLOGY

Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

(2008) Jonathan Berek et al.   JOURNAL OF CLINICAL ONCOLOGY